# A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

> **NCT06670950** · PHASE1 · RECRUITING · sponsor: **Synendos Therapeutics AG** · enrollment: 90 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SYT-510
- **DRUG:** SYT-510
- **DRUG:** SYT-510
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06670950
- **Lead sponsor:** Synendos Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06670950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06670950, "A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06670950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*